ARTICLE | Company News
Cell Pathways to market Aventis' Nilandron
July 5, 2000 7:00 AM UTC
CLPA obtained rights to market AVE's Nilandron nilutamide to urologists in the U.S. and Puerto Rico to treat prostate cancer. CLPA will receive a percentage of sales. ...